Global PD-1 & PD-L1 Inhibitors Market by Product (Atezolizumab, Avelumab, Durvalumab), Distribution Channel (Hospital Pharmacies, Online Pharmacies, Retail Pharmacies) - Forecast 2024-2030- Product Image

Sale

Global PD-1 & PD-L1 Inhibitors Market by Product (Atezolizumab, Avelumab, Durvalumab), Distribution Channel (Hospital Pharmacies, Online Pharmacies, Retail Pharmacies) - Forecast 2024-2030

Report
196 Pages
March 2024
Region: Global
360iResearch™
ID: 5674438

UP TO €845EUR$875USD£723GBP OFF until Dec 31^st 2024

The PD-1 & PD-L1 Inhibitors Market size was estimated at USD 37.11 billion in 2023, USD 44.61 billion in 2024, and is expected to grow at a CAGR of 20.59% to reach USD 137.65 billion by 2030.

FPNV Positioning Matrix

The FPNV Positioning Matrix is pivotal in evaluating the PD-1 & PD-L1 Inhibitors Market. It offers a comprehensive assessment of vendors, examining key metrics related to Business Strategy and Product Satisfaction. This in-depth analysis empowers users to make well-informed decisions aligned with their requirements. Based on the evaluation, the vendors are then categorized into four distinct quadrants representing varying levels of success: Forefront (F), Pathfinder (P), Niche (N), or Vital (V).

Market Share Analysis

The Market Share Analysis is a comprehensive tool that provides an insightful and in-depth examination of the current state of vendors in the PD-1 & PD-L1 Inhibitors Market. By meticulously comparing and analyzing vendor contributions in terms of overall revenue, customer base, and other key metrics, we can offer companies a greater understanding of their performance and the challenges they face when competing for market share. Additionally, this analysis provides valuable insights into the competitive nature of the sector, including factors such as accumulation, fragmentation dominance, and amalgamation traits observed over the base year period studied. With this expanded level of detail, vendors can make more informed decisions and devise effective strategies to gain a competitive edge in the market.

Key Company Profiles

The report delves into recent significant developments in the PD-1 & PD-L1 Inhibitors Market, highlighting leading vendors and their innovative profiles. These include Akeso Inc., Alphamab Oncology, Amgen Inc., AstraZeneca PLC, BeiGene Ltd., Bristol Myers Squibb Company, Eli Lilly and Company, F. Hoffmann La Roche Ltd., Gilead Sciences Inc., GlaxoSmithKline PLC, Innovent Biologics Inc., Merck KGaA, Novartis AG, Pfizer Inc., Regeneron Pharmaceuticals Inc., and Sanofi S.A.

Market Segmentation & Coverage

This research report categorizes the PD-1 & PD-L1 Inhibitors Market to forecast the revenues and analyze trends in each of the following sub-markets:

Product
- Atezolizumab
- Avelumab
- Durvalumab
- Nivolumab
- Pembrolizumab
Distribution Channel
- Hospital Pharmacies
- Online Pharmacies
- Retail Pharmacies

Region
- Americas
  - Argentina
  - Brazil
  - Canada
  - Mexico
  - United States
    - California
    - Florida
    - Illinois
    - New York
    - Ohio
    - Pennsylvania
    - Texas
- Asia-Pacific
  - Australia
  - China
  - India
  - Indonesia
  - Japan
  - Malaysia
  - Philippines
  - Singapore
  - South Korea
  - Taiwan
  - Thailand
  - Vietnam
- Europe, Middle East & Africa
  - Denmark
  - Egypt
  - Finland
  - France
  - Germany
  - Israel
  - Italy
  - Netherlands
  - Nigeria
  - Norway
  - Poland
  - Qatar
  - Russia
  - Saudi Arabia
  - South Africa
  - Spain
  - Sweden
  - Switzerland
  - Turkey
  - United Arab Emirates
  - United Kingdom

The report offers valuable insights on the following aspects:

Market Penetration: It presents comprehensive information on the market provided by key players.
Market Development: It delves deep into lucrative emerging markets and analyzes the penetration across mature market segments.
Market Diversification: It provides detailed information on new product launches, untapped geographic regions, recent developments, and investments.
Competitive Assessment & Intelligence: It conducts an exhaustive assessment of market shares, strategies, products, certifications, regulatory approvals, patent landscape, and manufacturing capabilities of the leading players.
Product Development & Innovation: It offers intelligent insights on future technologies, R&D activities, and breakthrough product developments.

The report addresses key questions such as:

What is the market size and forecast of the PD-1 & PD-L1 Inhibitors Market?
Which products, segments, applications, and areas should one consider investing in over the forecast period in the PD-1 & PD-L1 Inhibitors Market?
What are the technology trends and regulatory frameworks in the PD-1 & PD-L1 Inhibitors Market?
What is the market share of the leading vendors in the PD-1 & PD-L1 Inhibitors Market?
Which modes and strategic moves are suitable for entering the PD-1 & PD-L1 Inhibitors Market?

Please note: For this report, the purchase of an Enterprise license allows up to ten worldwide users of an organization access to the report

Please note: This report can be updated on request. Please contact our Customer Experience team using the Ask a Question widget on our website.

With the purchase of this report at the Multi-user License or greater level, you will have access to one hour with an expert analyst who will help you link key findings in the report to the business issues you're addressing. This will need to be used within three months of purchase.

This report also includes a complimentary Excel file with data from the report for purchasers at the Site License or greater level.

1. Preface

1.1. Objectives of the Study
1.2. Market Segmentation & Coverage
1.3. Years Considered for the Study
1.4. Currency & Pricing
1.5. Language
1.6. Limitations
1.7. Assumptions
1.8. Stakeholders

2. Research Methodology

2.1. Define: Research Objective
2.2. Determine: Research Design
2.3. Prepare: Research Instrument
2.4. Collect: Data Source
2.5. Analyze: Data Interpretation
2.6. Formulate: Data Verification
2.7. Publish: Research Report
2.8. Repeat: Report Update

3. Executive Summary

4. Market Overview

4.1. Introduction
4.2. PD-1 & PD-L1 Inhibitors Market, by Region

5. Market Insights

5.1. Market Dynamics
5.1.1. Drivers
5.1.1.1. Increasing prevalence of cancer coupled with growing geriatric population
5.1.1.2. Growing presence of patient assistance programs
5.1.1.3. Rising public awareness and increasing healthcare expenses
5.1.2. Restraints
5.1.2.1. High cost of cancer immunotherapy
5.1.3. Opportunities
5.1.3.1. Increasing research activities in pd1 and pdl1 inhibitors
5.1.3.2. Technological innovations and advancements in cancer screening procedures
5.1.4. Challenges
5.1.4.1. Stringent regulatory scenario
5.2. Market Segmentation Analysis
5.3. Market Trend Analysis
5.4. Cumulative Impact of High Inflation
5.5. Porter’s Five Forces Analysis
5.5.1. Threat of New Entrants
5.5.2. Threat of Substitutes
5.5.3. Bargaining Power of Customers
5.5.4. Bargaining Power of Suppliers
5.5.5. Industry Rivalry
5.6. Value Chain & Critical Path Analysis
5.7. Regulatory Framework

6. PD-1 & PD-L1 Inhibitors Market, by Product

6.1. Introduction
6.2. Atezolizumab
6.3. Avelumab
6.4. Durvalumab
6.5. Nivolumab
6.6. Pembrolizumab

7. PD-1 & PD-L1 Inhibitors Market, by Distribution Channel

7.1. Introduction
7.2. Hospital Pharmacies
7.3. Online Pharmacies
7.4. Retail Pharmacies

8. Americas PD-1 & PD-L1 Inhibitors Market

8.1. Introduction
8.2. Argentina
8.3. Brazil
8.4. Canada
8.5. Mexico
8.6. United States

9. Asia-Pacific PD-1 & PD-L1 Inhibitors Market

9.1. Introduction
9.2. Australia
9.3. China
9.4. India
9.5. Indonesia
9.6. Japan
9.7. Malaysia
9.8. Philippines
9.9. Singapore
9.10. South Korea
9.11. Taiwan
9.12. Thailand
9.13. Vietnam

10. Europe, Middle East & Africa PD-1 & PD-L1 Inhibitors Market

10.1. Introduction
10.2. Denmark
10.3. Egypt
10.4. Finland
10.5. France
10.6. Germany
10.7. Israel
10.8. Italy
10.9. Netherlands
10.10. Nigeria
10.11. Norway
10.12. Poland
10.13. Qatar
10.14. Russia
10.15. Saudi Arabia
10.16. South Africa
10.17. Spain
10.18. Sweden
10.19. Switzerland
10.20. Turkey
10.21. United Arab Emirates
10.22. United Kingdom

11. Competitive Landscape

11.1. FPNV Positioning Matrix
11.2. Market Share Analysis, By Key Player
11.3. Competitive Scenario Analysis, By Key Player

12. Competitive Portfolio

12.1. Key Company Profiles
12.1.1. Akeso Inc.
12.1.2. Alphamab Oncology
12.1.3. Amgen Inc.
12.1.4. AstraZeneca PLC
12.1.5. BeiGene Ltd.
12.1.6. Bristol Myers Squibb Company
12.1.7. Eli Lilly and Company
12.1.8. F. Hoffmann La Roche Ltd.
12.1.9. Gilead Sciences Inc.
12.1.10. GlaxoSmithKline PLC
12.1.11. Innovent Biologics Inc.
12.1.12. Merck KGaA
12.1.13. Novartis AG
12.1.14. Pfizer Inc.
12.1.15. Regeneron Pharmaceuticals Inc.
12.1.16. Sanofi S.A.
12.2. Key Product Portfolio

13. Appendix

13.1. Discussion Guide
13.2. License & Pricing

List of Figures

FIGURE 1. PD-1 & PD-L1 INHIBITORS MARKET RESEARCH PROCESS
FIGURE 2. PD-1 & PD-L1 INHIBITORS MARKET SIZE, 2023 VS 2030
FIGURE 3. PD-1 & PD-L1 INHIBITORS MARKET SIZE, 2018-2030 (USD MILLION)
FIGURE 4. PD-1 & PD-L1 INHIBITORS MARKET SIZE, BY REGION, 2023 VS 2030 (%)
FIGURE 5. PD-1 & PD-L1 INHIBITORS MARKET SIZE, BY REGION, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 6. PD-1 & PD-L1 INHIBITORS MARKET DYNAMICS
FIGURE 7. PD-1 & PD-L1 INHIBITORS MARKET SIZE, BY PRODUCT, 2023 VS 2030 (%)
FIGURE 8. PD-1 & PD-L1 INHIBITORS MARKET SIZE, BY PRODUCT, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 9. PD-1 & PD-L1 INHIBITORS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2023 VS 2030 (%)
FIGURE 10. PD-1 & PD-L1 INHIBITORS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 11. AMERICAS PD-1 & PD-L1 INHIBITORS MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
FIGURE 12. AMERICAS PD-1 & PD-L1 INHIBITORS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 13. UNITED STATES PD-1 & PD-L1 INHIBITORS MARKET SIZE, BY STATE, 2023 VS 2030 (%)
FIGURE 14. UNITED STATES PD-1 & PD-L1 INHIBITORS MARKET SIZE, BY STATE, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 15. ASIA-PACIFIC PD-1 & PD-L1 INHIBITORS MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
FIGURE 16. ASIA-PACIFIC PD-1 & PD-L1 INHIBITORS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 17. EUROPE, MIDDLE EAST & AFRICA PD-1 & PD-L1 INHIBITORS MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
FIGURE 18. EUROPE, MIDDLE EAST & AFRICA PD-1 & PD-L1 INHIBITORS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 19. PD-1 & PD-L1 INHIBITORS MARKET, FPNV POSITIONING MATRIX, 2023
FIGURE 20. PD-1 & PD-L1 INHIBITORS MARKET SHARE, BY KEY PLAYER, 2023

List of Tables

TABLE 1. PD-1 & PD-L1 INHIBITORS MARKET SEGMENTATION & COVERAGE
TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2023
TABLE 3. PD-1 & PD-L1 INHIBITORS MARKET SIZE, 2018-2030 (USD MILLION)
TABLE 4. GLOBAL PD-1 & PD-L1 INHIBITORS MARKET SIZE, BY REGION, 2018-2030 (USD MILLION)
TABLE 5. PD-1 & PD-L1 INHIBITORS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
TABLE 6. PD-1 & PD-L1 INHIBITORS MARKET SIZE, BY ATEZOLIZUMAB, BY REGION, 2018-2030 (USD MILLION)
TABLE 7. PD-1 & PD-L1 INHIBITORS MARKET SIZE, BY AVELUMAB, BY REGION, 2018-2030 (USD MILLION)
TABLE 8. PD-1 & PD-L1 INHIBITORS MARKET SIZE, BY DURVALUMAB, BY REGION, 2018-2030 (USD MILLION)
TABLE 9. PD-1 & PD-L1 INHIBITORS MARKET SIZE, BY NIVOLUMAB, BY REGION, 2018-2030 (USD MILLION)
TABLE 10. PD-1 & PD-L1 INHIBITORS MARKET SIZE, BY PEMBROLIZUMAB, BY REGION, 2018-2030 (USD MILLION)
TABLE 11. PD-1 & PD-L1 INHIBITORS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 12. PD-1 & PD-L1 INHIBITORS MARKET SIZE, BY HOSPITAL PHARMACIES, BY REGION, 2018-2030 (USD MILLION)
TABLE 13. PD-1 & PD-L1 INHIBITORS MARKET SIZE, BY ONLINE PHARMACIES, BY REGION, 2018-2030 (USD MILLION)
TABLE 14. PD-1 & PD-L1 INHIBITORS MARKET SIZE, BY RETAIL PHARMACIES, BY REGION, 2018-2030 (USD MILLION)
TABLE 15. AMERICAS PD-1 & PD-L1 INHIBITORS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
TABLE 16. AMERICAS PD-1 & PD-L1 INHIBITORS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 17. AMERICAS PD-1 & PD-L1 INHIBITORS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
TABLE 18. ARGENTINA PD-1 & PD-L1 INHIBITORS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
TABLE 19. ARGENTINA PD-1 & PD-L1 INHIBITORS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 20. BRAZIL PD-1 & PD-L1 INHIBITORS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
TABLE 21. BRAZIL PD-1 & PD-L1 INHIBITORS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 22. CANADA PD-1 & PD-L1 INHIBITORS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
TABLE 23. CANADA PD-1 & PD-L1 INHIBITORS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 24. MEXICO PD-1 & PD-L1 INHIBITORS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
TABLE 25. MEXICO PD-1 & PD-L1 INHIBITORS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 26. UNITED STATES PD-1 & PD-L1 INHIBITORS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
TABLE 27. UNITED STATES PD-1 & PD-L1 INHIBITORS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 28. UNITED STATES PD-1 & PD-L1 INHIBITORS MARKET SIZE, BY STATE, 2018-2030 (USD MILLION)
TABLE 29. ASIA-PACIFIC PD-1 & PD-L1 INHIBITORS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
TABLE 30. ASIA-PACIFIC PD-1 & PD-L1 INHIBITORS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 31. ASIA-PACIFIC PD-1 & PD-L1 INHIBITORS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
TABLE 32. AUSTRALIA PD-1 & PD-L1 INHIBITORS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
TABLE 33. AUSTRALIA PD-1 & PD-L1 INHIBITORS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 34. CHINA PD-1 & PD-L1 INHIBITORS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
TABLE 35. CHINA PD-1 & PD-L1 INHIBITORS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 36. INDIA PD-1 & PD-L1 INHIBITORS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
TABLE 37. INDIA PD-1 & PD-L1 INHIBITORS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 38. INDONESIA PD-1 & PD-L1 INHIBITORS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
TABLE 39. INDONESIA PD-1 & PD-L1 INHIBITORS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 40. JAPAN PD-1 & PD-L1 INHIBITORS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
TABLE 41. JAPAN PD-1 & PD-L1 INHIBITORS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 42. MALAYSIA PD-1 & PD-L1 INHIBITORS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
TABLE 43. MALAYSIA PD-1 & PD-L1 INHIBITORS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 44. PHILIPPINES PD-1 & PD-L1 INHIBITORS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
TABLE 45. PHILIPPINES PD-1 & PD-L1 INHIBITORS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 46. SINGAPORE PD-1 & PD-L1 INHIBITORS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
TABLE 47. SINGAPORE PD-1 & PD-L1 INHIBITORS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 48. SOUTH KOREA PD-1 & PD-L1 INHIBITORS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
TABLE 49. SOUTH KOREA PD-1 & PD-L1 INHIBITORS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 50. TAIWAN PD-1 & PD-L1 INHIBITORS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
TABLE 51. TAIWAN PD-1 & PD-L1 INHIBITORS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 52. THAILAND PD-1 & PD-L1 INHIBITORS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
TABLE 53. THAILAND PD-1 & PD-L1 INHIBITORS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 54. VIETNAM PD-1 & PD-L1 INHIBITORS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
TABLE 55. VIETNAM PD-1 & PD-L1 INHIBITORS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 56. EUROPE, MIDDLE EAST & AFRICA PD-1 & PD-L1 INHIBITORS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
TABLE 57. EUROPE, MIDDLE EAST & AFRICA PD-1 & PD-L1 INHIBITORS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 58. EUROPE, MIDDLE EAST & AFRICA PD-1 & PD-L1 INHIBITORS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
TABLE 59. DENMARK PD-1 & PD-L1 INHIBITORS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
TABLE 60. DENMARK PD-1 & PD-L1 INHIBITORS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 61. EGYPT PD-1 & PD-L1 INHIBITORS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
TABLE 62. EGYPT PD-1 & PD-L1 INHIBITORS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 63. FINLAND PD-1 & PD-L1 INHIBITORS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
TABLE 64. FINLAND PD-1 & PD-L1 INHIBITORS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 65. FRANCE PD-1 & PD-L1 INHIBITORS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
TABLE 66. FRANCE PD-1 & PD-L1 INHIBITORS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 67. GERMANY PD-1 & PD-L1 INHIBITORS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
TABLE 68. GERMANY PD-1 & PD-L1 INHIBITORS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 69. ISRAEL PD-1 & PD-L1 INHIBITORS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
TABLE 70. ISRAEL PD-1 & PD-L1 INHIBITORS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 71. ITALY PD-1 & PD-L1 INHIBITORS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
TABLE 72. ITALY PD-1 & PD-L1 INHIBITORS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 73. NETHERLANDS PD-1 & PD-L1 INHIBITORS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
TABLE 74. NETHERLANDS PD-1 & PD-L1 INHIBITORS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 75. NIGERIA PD-1 & PD-L1 INHIBITORS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
TABLE 76. NIGERIA PD-1 & PD-L1 INHIBITORS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 77. NORWAY PD-1 & PD-L1 INHIBITORS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
TABLE 78. NORWAY PD-1 & PD-L1 INHIBITORS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 79. POLAND PD-1 & PD-L1 INHIBITORS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
TABLE 80. POLAND PD-1 & PD-L1 INHIBITORS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 81. QATAR PD-1 & PD-L1 INHIBITORS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
TABLE 82. QATAR PD-1 & PD-L1 INHIBITORS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 83. RUSSIA PD-1 & PD-L1 INHIBITORS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
TABLE 84. RUSSIA PD-1 & PD-L1 INHIBITORS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 85. SAUDI ARABIA PD-1 & PD-L1 INHIBITORS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
TABLE 86. SAUDI ARABIA PD-1 & PD-L1 INHIBITORS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 87. SOUTH AFRICA PD-1 & PD-L1 INHIBITORS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
TABLE 88. SOUTH AFRICA PD-1 & PD-L1 INHIBITORS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 89. SPAIN PD-1 & PD-L1 INHIBITORS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
TABLE 90. SPAIN PD-1 & PD-L1 INHIBITORS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 91. SWEDEN PD-1 & PD-L1 INHIBITORS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
TABLE 92. SWEDEN PD-1 & PD-L1 INHIBITORS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 93. SWITZERLAND PD-1 & PD-L1 INHIBITORS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
TABLE 94. SWITZERLAND PD-1 & PD-L1 INHIBITORS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 95. TURKEY PD-1 & PD-L1 INHIBITORS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
TABLE 96. TURKEY PD-1 & PD-L1 INHIBITORS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 97. UNITED ARAB EMIRATES PD-1 & PD-L1 INHIBITORS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
TABLE 98. UNITED ARAB EMIRATES PD-1 & PD-L1 INHIBITORS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 99. UNITED KINGDOM PD-1 & PD-L1 INHIBITORS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
TABLE 100. UNITED KINGDOM PD-1 & PD-L1 INHIBITORS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 101. PD-1 & PD-L1 INHIBITORS MARKET, FPNV POSITIONING MATRIX, 2023
TABLE 102. PD-1 & PD-L1 INHIBITORS MARKET SHARE, BY KEY PLAYER, 2023
TABLE 103. PD-1 & PD-L1 INHIBITORS MARKET LICENSE & PRICING

Companies Mentioned

Akeso Inc.
Alphamab Oncology
Amgen Inc.
AstraZeneca PLC
BeiGene Ltd.
Bristol Myers Squibb Company
Eli Lilly and Company
F. Hoffmann La Roche Ltd.
Gilead Sciences Inc.
GlaxoSmithKline PLC
Innovent Biologics Inc.
Merck KGaA
Novartis AG
Pfizer Inc.
Regeneron Pharmaceuticals Inc.
Sanofi S.A.

Methodology

LOADING...

Table Information

Report Attribute	Details
No. of Pages	196
Published	March 2024
Forecast Period	2024 - 2030
Estimated Market Value ( USD ) in 2024	$ 44.61 Billion
Forecasted Market Value ( USD ) by 2030	$ 137.65 Billion
Compound Annual Growth Rate	20.5%
Regions Covered	Global
No. of Companies Mentioned	16

PURCHASE OPTIONS

Single User License Online Access - 1 Year

Single User License PDF, Excel And Online Access - 1 Year

1 - 5 User License PDF, Excel And Online Access - 1 Year

Site License PDF, Excel And Online Access - 1 Year

Enterprise License PDF, Excel And Online Access - 1 Year

need a quote ?

License	Format	Properties	Price
SINGLE USER LICENSE Online Access - 1 Year	The product can be accessed through a secure website. Username and password will be sent via email. The access period is one year.	This is a single user license, allowing one user access to the product.	€3259EUR$3,374USD£2,787GBP €3621EUR$3,749USD£3,097GBP
SINGLE USER LICENSE PDF, Excel and Online Access - 1 Year	The product can be accessed through a secure website. Username and password will be sent via email. The access period is one year.	This is a single user license, allowing one user access to the product.	€4129EUR$4,274USD£3,530GBP €4587EUR$4,749USD£3,923GBP
1 - 5 USER LICENSE PDF, Excel and Online Access - 1 Year	The product can be accessed through a secure website. Username and password will be sent via email. The access period is one year.	This is a 1-5 user license, allowing up to five users have access to the product.	€4998EUR$5,174USD£4,274GBP €5553EUR$5,749USD£4,749GBP
SITE LICENSE PDF, Excel and Online Access - 1 Year	The product can be accessed through a secure website. Username and password will be sent via email. The access period is one year.	This is a site license, allowing all users within a given geographical location of your organization access to the product.	€5867EUR$6,074USD£5,017GBP €6519EUR$6,749USD£5,575GBP
ENTERPRISE LICENSE PDF, Excel and Online Access - 1 Year	The product can be accessed through a secure website. Username and password will be sent via email. The access period is one year.	This is an enterprise license, allowing all employees within your organization access to the product.	€7606EUR$7,874USD£6,504GBP €8451EUR$8,749USD£7,227GBP

FPNV Positioning Matrix

Market Share Analysis

Key Company Profiles

Market Segmentation & Coverage

The report offers valuable insights on the following aspects:

The report addresses key questions such as:

Table of Contents

Companies Mentioned

Methodology

Table Information

Related Topics

Related Reports

Global PD-1 and PD-L1 Inhibitors Market Report and Forecast 2023-2031

PD-1 And PD-L1 Inhibitors - Market Share Analysis, Industry Trends & Statistics, Growth Forecasts 2019 - 2029

PD-1 and PD-L1 inhibitors - Pipeline Insight, 2024

PD-1 and PD-L1 Inhibitors - Competitive Landscape, 2024

2023 Global Forecast for Pd-1 And Pd-L1 Inhibitors Market (2024-2029 Outlook) - High Tech & Emerging Markets Report